Abstract 247P
Background
Adenocarcinoma is an uncommon histologic variant and accounts for 0.5-2% of bladder cancers in the United States. Due to its rarity, there is limited data in the literature specifically focused on bladder adenocarcinoma treatment. So, the aim of this study is focused on evaluating the impact of chemoradiotherapy compared to multiple treatment modalities on the survival of patients with primary bladder adenocarcinoma.
Methods
The Surveillance, Epidemiology, and End Results (SEER) Program 17 registries database was utilized to identify primary bladder adenocarcinoma cases from (2000-2020). The disease stages and sociodemographic data were collected. The patients were subgrouped according to the treatment modality: primary chemotherapy, surgery only, adjuvant chemotherapy, adjuvant radiotherapy, and adjuvant chemoradiotherapy. SPSS Version 23 was used for data analysis. log-rank Kaplan-Meir curve was used for survival analysis.
Results
A total of 2500 cases of bladder adenocarcinoma were identified. Overall, the 5-year relative survival was 43.1%. With multiple treatment options, we found surgery with no systemic therapy had a better survival outcome (47.4%) compared to adjuvant chemotherapy (38%), adjuvant chemoradiotherapy (31.4), adjuvant radiotherapy (21.5%), and least primary chemotherapy (4.9%) (P <0.001). In the group that had surgical management with no systemic therapy, the localized stage had significantly improved survival compared to the regional and distant spread (62%, 40%, and 10.8%, respectively; P <0.001).
Conclusions
This study provides a comprehensive evaluation of multiple treatment modalities, and the results highlight surgery with no systemic therapy as the modality of choice for improved survival outcome. This eliminates the burden of adjuvant therapy with unfavorable side effects. However, few selected patients may use chemo(radio)therapy with special considerations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes
Presenter: Ambedkar Yadala
Session: Poster Display
Resources:
Abstract
299P - Sexual dysfunction assessment in longterm survivors of carcinoma cervix using LENT SOMA scale
Presenter: Niharika Sethi
Session: Poster Display
Resources:
Abstract
300P - Assessing ovarian function in Vietnamese cervical cancer patients who underwent ovary transposition prior to pelvic radiation therapy
Presenter: Cuong Nguyen
Session: Poster Display
Resources:
Abstract
301P - Correlation between cervical cancer recurrence after radiation therapy and vaginal microbiome
Presenter: Xiaoxian Xu
Session: Poster Display
Resources:
Abstract
302P - Expression of ERCC4 gene and its correlation with clinical and pathological parameters in cervical cancer
Presenter: Himanshu Mishra
Session: Poster Display
Resources:
Abstract
303P - Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy
Presenter: Hui Guo
Session: Poster Display
Resources:
Abstract
305P - A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study
Presenter: Yoshikazu Nagase
Session: Poster Display
Resources:
Abstract
306P - Adjuvant treatment and impact on relapse in stage IA uterine papillary serous and clear cell carcinomas: A single center retrospective study
Presenter: Sachin Khurana
Session: Poster Display
Resources:
Abstract
307P - Hormonal therapy vs combination chemotherapy in metastatic leiomyosarcomas: A systematic review
Presenter: Patricia Angel
Session: Poster Display
Resources:
Abstract
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract